drugset / Trial / NCT01638715

A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action

NCT01638715

Phase 4 Completed 115 enrolled Medical University of Vienna
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to find biological response patterns of patients with rheumatoid arthritis to drugs with different biologic modes of action. This study should help to predict therapeutic responses and to find the right therapy for the right patient.

Timeline

Start
2012-05
Primary completion
2018-08-01
Completion
2018-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Abatacept Other / unclassified 125 mg Intravenous
Subject Abatacept Other / unclassified 500 mg Intravenous
Subject Abatacept Other / unclassified 750 mg Intravenous
Subject Infliximab Monoclonal antibody 5 mg/kg Intravenous
Subject Rituximab Monoclonal antibody 1000 mg Intravenous
Subject Tocilizumab Monoclonal antibody 8 mg/kg Intravenous
Subject Tocilizumab Monoclonal antibody 162 mg Intravenous

Indications